OmniSeq

United States
Spicer, Minnesota, United States, 14203

Company profile

OmniSeq company profile

OmniSeq offers physicians and their patients of the most actionable tumor-profiling information possible. OmniSeq, an innovation of Roswell Park Cancer Institute, is a molecular diagnostic laboratory. It endeavors to find the right drug or the right trial for every patient. It also offers NY State CLEP approved assays, including OmniSeq Comprehensive, a 144 gene NGS assay that covers almost all known genetic alterations associated with an FDA-approved targeted therapy or genotype directed clinical trial. OmniSeq is also making significant investments to create better diagnostics for immuno-oncology therapy selection. The company was founded in 2015 and is based in Buffalo, New York.

Business identity

Contact email
[email protected]
Phone number
1(800)781-1259
Operating status
Closed
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
2015-01-01, Year

Headquarters

Postal code
14203
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
3
Total equity funding
$11.6M
Last funding
Series Unknown / $1.6M / 2019-06-20
Last equity funding
Series Unknown / $1.6M
Investors
2
Lead investors
1
Founders
2
Articles
8
Exited on
2021-07-19

Founders and investors

Founders

Jeffrey ConroyMary Nesline

Lead investors

LabCorp

Investors

LabCorpRoswell Park Cancer Institute